306 related articles for article (PubMed ID: 15019322)
1. A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis.
Akpek EK; Dart JK; Watson S; Christen W; Dursun D; Yoo S; O'Brien TP; Schein OD; Gottsch JD
Ophthalmology; 2004 Mar; 111(3):476-82. PubMed ID: 15019322
[TBL] [Abstract][Full Text] [Related]
2. A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis.
Hingorani M; Moodaley L; Calder VL; Buckley RJ; Lightman S
Ophthalmology; 1998 Sep; 105(9):1715-20. PubMed ID: 9754182
[TBL] [Abstract][Full Text] [Related]
3. A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis.
Ebihara N; Ohashi Y; Uchio E; Okamoto S; Kumagai N; Shoji J; Takamura E; Nakagawa Y; Nanba K; Fukushima A; Fujishima H
J Ocul Pharmacol Ther; 2009 Aug; 25(4):365-72. PubMed ID: 19441889
[TBL] [Abstract][Full Text] [Related]
4. Topical calcineurin inhibitors in the treatment of steroid-dependent atopic keratoconjunctivitis.
Tzu JH; Utine CA; Stern ME; Akpek EK
Cornea; 2012 Jun; 31(6):649-54. PubMed ID: 22378107
[TBL] [Abstract][Full Text] [Related]
5. Management of severe allergic conjunctivitis with topical cyclosporin a 0.05% eyedrops.
Ozcan AA; Ersoz TR; Dulger E
Cornea; 2007 Oct; 26(9):1035-8. PubMed ID: 17893529
[TBL] [Abstract][Full Text] [Related]
6. [Cyclosporin A 2% eyedrops in therapy of atopic and vernal keratoconjunctivitis].
Tomida I; Schlote T; Bräuning J; Heide PE; Zierhut M
Ophthalmologe; 2002 Oct; 99(10):761-7. PubMed ID: 12376851
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis.
Shulman DG; Lothringer LL; Rubin JM; Briggs RB; Howes J; Novack GD; Hart K
Ophthalmology; 1999 Feb; 106(2):362-9. PubMed ID: 9951491
[TBL] [Abstract][Full Text] [Related]
8. The immunomodulatory effect of topical cyclosporin A in atopic keratoconjunctivitis.
Hingorani M; Calder VL; Buckley RJ; Lightman S
Invest Ophthalmol Vis Sci; 1999 Feb; 40(2):392-9. PubMed ID: 9950598
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis.
Pucci N; Novembre E; Cianferoni A; Lombardi E; Bernardini R; Caputo R; Campa L; Vierucci A
Ann Allergy Asthma Immunol; 2002 Sep; 89(3):298-303. PubMed ID: 12269651
[TBL] [Abstract][Full Text] [Related]
10. Topical cyclosporine a in the treatment of superior limbic keratoconjunctivitis: a long-term follow-up.
Sahin A; Bozkurt B; Irkec M
Cornea; 2008 Feb; 27(2):193-5. PubMed ID: 18216575
[TBL] [Abstract][Full Text] [Related]
11. Topical ciclosporin in the treatment of vernal keratoconjunctivitis in Rwanda, Central Africa: a prospective, randomised, double-masked, controlled clinical trial.
De Smedt S; Nkurikiye J; Fonteyne Y; Tuft S; De Bacquer D; Gilbert C; Kestelyn P
Br J Ophthalmol; 2012 Mar; 96(3):323-8. PubMed ID: 22001151
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial of low-dose, topical mitomycin-C in the treatment of severe vernal keratoconjunctivitis.
Akpek EK; Hasiripi H; Christen WG; Kalayci D
Ophthalmology; 2000 Feb; 107(2):263-9. PubMed ID: 10690822
[TBL] [Abstract][Full Text] [Related]
13. Topical cyclosporine A in severe steroid-dependent childhood phlyctenular keratoconjunctivitis.
Doan S; Gabison E; Gatinel D; Duong MH; Abitbol O; Hoang-Xuan T
Am J Ophthalmol; 2006 Jan; 141(1):62-66. PubMed ID: 16386977
[TBL] [Abstract][Full Text] [Related]
14. Topical 2% cyclosporine A in preservative-free artificial tears for the treatment of vernal keratoconjunctivitis.
Kiliç A; Gürler B
Can J Ophthalmol; 2006 Dec; 41(6):693-8. PubMed ID: 17224949
[TBL] [Abstract][Full Text] [Related]
15. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
Barber LD; Pflugfelder SC; Tauber J; Foulks GN
Ophthalmology; 2005 Oct; 112(10):1790-4. PubMed ID: 16102833
[TBL] [Abstract][Full Text] [Related]
16. Systemic tacrolimus in the treatment of severe atopic keratoconjunctivitis.
Stumpf T; Luqmani N; Sumich P; Cook S; Tole D
Cornea; 2006 Dec; 25(10):1147-9. PubMed ID: 17172887
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
Avunduk AM; Tekelioglu Y; Turk A; Akyol N
Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis.
Salib GM; McDonald MB; Smolek M
J Cataract Refract Surg; 2006 May; 32(5):772-8. PubMed ID: 16765793
[TBL] [Abstract][Full Text] [Related]
19. Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A.
Brignole F; Pisella PJ; De Saint Jean M; Goldschild M; Goguel A; Baudouin C
Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):90-5. PubMed ID: 11133852
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.
Greiner JV; Udell IJ
Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
